ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study

Xiao, Lushan; Liao, Yanxia; Wang, Jiaren; Li, Qimei; Zhu, Hongbo; Hong, Chang; Li, Ruining; He, Jingzhe; Cui, Hao*; Dong, Hanzhi*; Zeng, Lin*; Liu, Li*南方医科大学; 1
Cancer Immunology, Immunotherapy2023-7DOI: 10.1007/s00262-023-03417-3
2被引17阅读
引用收藏
分享

摘要

BackgroundThere is still no specific real-world data regarding the clinical activity of immune checkpoint inhibitors in the elderly with liver cancer. Our study aimed to compare the efficacy and safety of immune checkpoint inhibitors between patients aged >= 65 years and the younger group, while exploring their differences in genomic background and tumor microenvironment.MethodsThis retrospective study was conducted at two hospitals in China and included 540 patients treated with immune checkpoint inhibitors for primary liver cancer between January 2018 and December 2021. Patients' medical records were reviewed for clinical and radiological data and oncologic outcomes. The genomic and clinical data of patients with primary liver cancer were extracted and analyzed from TCGA-LIHC, GSE14520, and GSE140901 datasets.ResultsNinety-two patients were classified as elderly and showed better progression-free survival (P = 0.027) and disease control rate (P = 0.014). No difference was observed in overall survival (P = 0.69) or objective response rate (P = 0.423) between the two age groups. No significant difference was reported concerning the number (P = 0.824) and severity (P = 0.421) of adverse events. The enrichment analyses indicated that the elderly group was linked to lower expression of oncogenic pathways, such as PI3K-Akt, Wnt, and IL-17. The elderly had a higher tumor mutation burden than younger patients.ConclusionsOur results indicated that immune checkpoint inhibitors might exhibit better efficacy in the elderly with primary liver cancer, with no increased adverse events. Differences in genomic characteristics and tumor mutation burden may partially explain these results.

学科与关键词

关键词
Immune checkpoint inhibitorsElderlyPrimary liver cancerEfficacySafety
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Cancer Immunology, Immunotherapy
发表日期
2023-07
卷期
第 72 卷, 第 7 期
页码
2299-2308
DOI
10.1007/s00262-023-03417-3
语言
ENGLISH
成果收录
SCIE

作者

  • X

    Xiao, Lushan (第一作者)

    southern med univ

  • L

    Liao, Yanxia

    southern med univ

查看全部 12 位作者收起作者
  • W

    Wang, Jiaren

    southern med univ

  • L

    Li, Qimei

    southern med univ

  • Z

    Zhu, Hongbo

    1 · univ south china

  • H

    Hong, Chang

    southern med univ

  • L

    Li, Ruining

    southern med univ

  • H

    He, Jingzhe

    southern med univ

  • C

    Cui, Hao (通讯)

    southern med univ

  • D

    Dong, Hanzhi (通讯)

    2 · jiangxi canc hosp

  • Z

    Zeng, Lin (通讯)

    southern med univ

  • L

    Liu, Li (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417